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Abstract The ability of the chemokines SDF-1, MDC and
TARC to induce platelet aggregation depends strongly on low
levels of ADP. The ADP receptors involved have now been
characterized using the P2Y1 and P2TAC receptor antagonists,
A2P5P and AR-C69931MX. Stimulation of aggregation by the
chemokines at 10 s was not blocked by AR-C69931MX, but was
strongly inhibited by A2P5P. Pertussis toxin abolished the
chemokine-stimulated aggregation. We conclude that the P2Y1
ADP receptor plays a critical role in the initial phases of SDF-1-,
MDC- and TARC-induced platelet aggregation, which involve a
pertussis toxin-sensitive G protein. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Blood platelets play important roles in homeostasis, mini-
mizing blood loss and promoting wound healing [1]. In addi-
tion to these essential roles of platelets, they also contribute to
the development of atherosclerosis and may be involved in
in£ammation and infection [1,2]. During such conditions,
platelets may be activated, adhering to sites of injury, aggre-
gating to form large ¢brin-rich thrombi and releasing granule
contents. These granules contain in£ammatory mediators such
as chemokines as well as highly adhesive proteins such as von
Willebrand factor, ¢brinogen and P-selectin [3^5].
Chemokines are low-molecular weight proteins with impor-
tant roles, especially in response to tissue damage or infection
[6,7]. They exist in two main families according to the posi-
tions of conserved cysteine residues; CXC chemokines such as
IL-8 (interleukin-8) and SDF-1 (stromal-derived factor-1),
and CC chemokines such as MDC (macrophage-derived che-
mokine), TARC (thymus and activation-regulated chemokine)
and RANTES (regulated on activation, normal T cell ex-
pressed and secreted). Chemokines are ligands for G pro-
tein-coupled receptors whose activation may mediate the mi-
gration of leukocytes to the sites of injury and in£ammation
[7,8]. Recently, CXCR4, a receptor for SDF-1, and CCR4, a
receptor for MDC and TARC, have been shown to be ex-
pressed on platelets, and SDF-1, MDC and TARC can ini-
tiate platelet aggregation [9^11]. However, this ability is
strongly in£uenced by the presence of low levels of the pri-
mary platelet agonist ADP [11]. Low levels of ADP may be
present in blood [12], enabling platelet activation and aggre-
gation when chemokines are released into the circulation dur-
ing infection and in£ammation.
ADP is a primary platelet agonist which also enhances the
activation induced by other agonists such as thrombin and
collagen [13]. Moreover, platelet aggregation induced by
ADP can be greatly enhanced by epinephrine (EPI) which
by itself cannot induce platelet aggregation [14]. These obser-
vations support the hypothesis that ADP is an especially im-
portant factor for platelet function. Recently, several ADP
receptors on platelets have been described [15^18], including
the P2 receptors P2Y1 and P2TAC which are coupled to the
GKq and GKi proteins, respectively, and activation of both
receptors appears necessary for ADP-induced platelet aggre-
gation [15]. In the present study, we have investigated which
ADP receptors are involved in platelet activation by SDF-1,
MDC and TARC. Along with these chemokines, we also ex-
amined EPI, which is a well-known coagonist as a model to
compare the e¡ects of EPI and the chemokines.
2. Materials and methods
2.1. Materials
SDF-1, MDC and TARC were obtained from RpD Systems (Min-
neapolis, MN, USA) and from Research Diagnostics, Inc. (Flanders,
NJ, USA). MDC was also provided by Drs. D. Chantry and P. Gray
of the ICOS Corporation (Bothel, WA, USA). AR-C69931MX was
obtained from R+D Charnwood AstraZeneca (Loughorough, Leics,
UK). Pertussis toxin (Ptx) A protomer was obtained from List Bio-
logical Laboratories, Inc. (Campbell, CA, USA). Apyrase (grade VII),
indomethacin, prostacyclin (PGI2), EPI, A2P5P and other speciality
chemicals were from Sigma (St. Louis, MO, USA).
2.2. Preparation of platelets
Human venous blood was collected and anticoagulated with acid-
citrate dextrose (ACD) for a ¢nal citrate concentration of 11.5 mM
[19]. Platelet-rich plasma (PRP), prepared as described by centrifuga-
tion at 350Ug, was mixed with ACD (11.5 mM), apyrase (5 U/ml),
indomethacin (1 mg/ml) and PGI2 (0.3 Wg/ml), and centrifuged at
620Ug for 20 min. The resulting platelet pellet was washed with
ACD (1/2 volume of PRP) containing albumin (3 mg/ml) and apyrase
(5 U/ml) and centrifuged at 620Ug for 20 min. The ¢nal platelet pellet
was suspended in an Eagle’s/HEPES bu¡er containing 0.5 mg/ml ¢-
brinogen [20]. The ¢nal platelet concentrations were typically
3.2U108/ml, with a yield of 80^90% compared to PRP, and were
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stored at room temperature. All experiments were completed within
5 h.
2.3. Platelet aggregation
To assess platelet aggregation, 35 Wl of washed platelets were pre-
incubated for 10 min with saline, apyrase (5 U/ml) or the ADP antag-
onists A2P5P or AR-C69931MX at 37‡C. The preincubated platelets
were mixed with chemokines, EPI and/or agonists as indicated, giving
a ¢nal volume of 50 Wl, for 10 s under orbital shaking conditions
(1200 rpm) at 37‡C on a commercial shaker (Eppendorf, Thermo-
mixer R). The reactions were quenched with an equal volume of glu-
taraldehyde (1% ¢nal concentration) and platelet aggregation was
determined by the loss of platelet singlets using a resistive-particle
counter. This orbital shaking system gave similar amounts of platelet
aggregation as seen in a test-tube, stirring system, with stir bars ro-
tated at about 1000 rpm [11].
2.4. Treatment of platelets with Ptx
Experiments were carried out as described [21]. Washed platelets
were preincubated at 37‡C for 10 min and then for another 5 min in
the presence of the ADP-ribosylation bu¡er, containing 15 Wg/ml
saponin, 0.2 mM NAD and 0.5 mM ATP, either alone (vehicle) or
with PtxA protomer at 10 Wg/ml. The resulting platelets were activated
with agonists and aggregation determined as described above. Expo-
sure to vehicle caused about 30% singlet loss, possibly resulting from
the permeabilization procedure, causing leakage of compounds, in-
cluding ADP, from the platelet cytosol.
2.5. Presentation of data
Data are shown as means þ S.E.M., from 3^4 experiments, and the
Student’s t-test was performed to determine whether two groups of
experimental data were signi¢cantly di¡erent. Curve ¢tting was done
by using a Logistic function provided by the Origin software from
OriginLab Corporation (Northampton, MA, USA). IC50s repre-
sent concentrations giving 50% inhibition from the expression Y =
1/2(Ymax+Ymin).
3. Results
3.1. EPI potentiates ADP-induced platelet aggregation
EPI enhances platelet aggregation induced by primary ago-
nists including ADP and thrombin [14,22^24]. Therefore, we
examined whether the e¡ects of EPI on platelets were similar
to those of the chemokines SDF-1, MDC and TARC [11].
EPI by itself induced little aggregation (6 5% above control).
This was abolished when preparations were pretreated with
the ADP scavenger apyrase (Fig. 1), suggesting that low ADP
levels are present in the washed platelet preparations, as re-
ported by earlier work [14].
Low levels of ADP (0.05 WM) and thrombin (0.01 U/ml) by
themselves induced minimal aggregation (6 10%), compared
to the control (9.7%, Fig. 1). EPI potentiated platelet activa-
tion by ADP and thrombin (36% and 42% aggregation, re-
spectively), which for thrombin was partially inhibited by
apyrase pretreatment. These e¡ects of EPI on platelet aggre-
gation and the in£uence of apyrase are similar to what we
have recently observed for the chemokines SDF-1, MDC
and TARC [11].
3.2. Dose-dependent inhibition of early platelet aggregation by
ADP antagonists
The ADP receptor antagonists A2P5P and AR-C69931MX,
speci¢c for P2Y1 and P2TAC, respectively, were chosen
[25,26], and we established dose^response curves for blocking
the initial platelet aggregation induced by ADP alone (0.5
WM), which caused about 71% aggregation (Fig. 2a,b).
A2P5P caused almost complete inhibition, with an IC50 of
Fig. 1. E¡ects of EPI on platelet aggregation. Washed platelets were
preincubated with saline or apyrase (Apy) and mixed for 10 s with
saline, ADP (0.05 WM) or thrombin (0.01 U/ml), as indicated on the
left, either alone (gray bars) or in combination with 15 WM EPI
(black bars). Platelet aggregation was determined by the loss of
platelet singlets (*P6 0.05; **P6 0.01).
Fig. 2. Dose^response curves of ADP receptor antagonists A2P5P
and AR-C69931MX. Washed platelets were preincubated with saline
or the ADP antagonists A2P5P (a) or AR-C69931MX (b) and then
challenged with 0.5 WM ADP (F) or 15 WM EPI+0.05 WM ADP
(a). Platelet aggregation was assessed and the inhibition by the an-
tagonists was calculated by setting aggregation induced by ADP
(71.4 þ 0.9%) or EPI+ADP (46.7 þ 6.4%) as baseline aggregation
with 0% inhibition.
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6.7 WM. In contrast, AR-C69931MX was less e¡ective, only
causing about 55% inhibition and the IC50 was 6.9 nM. Next,
we tested how the antagonists a¡ected aggregation induced by
a combination of EPI and a very low dose of ADP (0.05 WM).
Such aggregation became very sensitive to the presence of
A2P5P, with IC50 of 0.5 WM (Fig. 2a), but was resistant to
inhibition by AR-C69931MX (Fig. 2b). Even though the IC50
was decreased (0.4 nM), the maximal inhibition was only
about 20%.
3.3. E¡ects of ADP receptor antagonists on early platelet
aggregation induced by the chemokines SDF-1, MDC and
TARC
MDC and TARC by themselves caused platelet aggregation
(42% and 30%, respectively), which was enhanced in the pres-
ence of low levels of ADP (0.05 WM, 72% and 62% aggrega-
tion, respectively, Fig. 3). However, SDF-1 was less e¡ective,
inducing only 18% aggregation by itself and 30% when com-
bined with 0.05 WM ADP (Fig. 3). We then tested the receptor
antagonists to evaluate which ADP receptors were responsible
for the stimulating e¡ect of the chemokines, choosing a dose
of each which gave maximal inhibition (Fig. 2). AR-
C69931MX did not inhibit early aggregation caused by
SDF-1, MDC and TARC, while A2P5P diminished aggrega-
tion caused by SDF-1 down to levels which are similar to
‘control saline’ (Fig. 1). In contrast, A2P5P only partially
blocked MDC- or TARC-induced aggregation (Fig. 3), to
values still signi¢cantly above ‘control saline’ (Fig. 1,
P6 0.05).
3.4. Ptx inhibits platelet aggregation induced by SDF-1,
MDC and TARC
We next investigated whether chemokine-induced aggrega-
tion involves activation of GKi proteins by using the bacterial
toxin Ptx [21]. Exposure to Ptx strongly inhibited platelet
aggregation induced by thrombin, SDF-1, MDC and TARC
by 82.3%, 88.9%, 73.0% and 67.0%, respectively (Fig. 4).
4. Discussion
In the present study, we have investigated the synergism
between low levels of ADP and the chemokines SDF-1,
MDC and TARC in the early phase of platelet aggregation,
using the ADP receptor antagonists A2P5P and AR-
C69931MX speci¢c to P2Y1 and P2TAC receptors, respec-
tively [25,26]. A2P5P strongly inhibited the stimulation caused
by the chemokines, while AR-C69931MX had minimal e¡ect
(Figs. 2 and 3), and Ptx markedly suppressed the ability of
SDF-1, MDC and TARC to stimulate platelet aggregation
(Fig. 4).
EPI-enhanced platelet aggregation induced by low levels of
ADP or thrombin was strongly decreased when the platelet
preparations were pretreated with apyrase (Fig. 1), suggesting
synergism between EPI, ADP and thrombin. Similar observa-
tions have been reported previously [13,14]. The inhibitory
e¡ects of A2P5P and AR-C69931MX on platelet aggregation
caused by ADP and EPI were then examined. The aggrega-
tion induced by ADP (0.5 WM) was inhibited in a dose-depen-
dent manner by the antagonists, with maximal inhibitions of
90% and 55% by A2P5P and AR-C69931MX, respectively.
This result shows that A2P5P was much more potent than
AR-C69931MX, suggesting that the activation of the ADP
receptor P2Y1 is involved during early aggregation (10 s)
rather than that of P2TAC. This ¢nding is similar to the report
showing that activation of P2Y1 can induce primary aggrega-
tion without activation of P2TAC [18]. In addition, a combi-
nation of EPI with a low level of ADP, which by themselves
caused minimal aggregation, resulted in aggregation that was
markedly inhibited by A2P5P (85%), but resistant to AR-
C69931MX (20% inhibition, Fig. 2a). As expected, the IC50
values for the antagonists were decreased by about 10-fold
when the lower dose of ADP (0.05 WM) was used, instead
of the higher dose of 0.5 WM. However, the maximal e¡ect
of AR-C69931MX was much less when EPI was present, de-
creasing from about 55% to 20% inhibition. These observa-
tions may be explained by the fact that EPI can also activate
GKi, the G protein coupled to P2TAC, such that when P2TAC
is blocked by the ADP receptor antagonist, EPI can partially
bypass the ‘block’.
Fig. 3. E¡ects of A2P5P and AR-C69931MX on platelet aggrega-
tion induced by SDF-1, MDC and TARC. Washed platelets were
preincubated with saline, A2P5P (100 WM) or AR-C69931MX
(1 WM) and reacted with 0.5 Wg/ml of SDF-1, MDC or TARC in
combinations with ADP (0.05 WM). Platelet aggregation was deter-
mined as in Fig. 1 (**P6 0.01; ***P6 0.005; #P6 0.05, compared
with ‘saline control’ in Fig. 1, P6 0.05).
Fig. 4. Ptx inhibits SDF-1-, MDC- and TARC-induced platelet ag-
gregation. Washed platelets were pretreated with vehicle (ADP-ribo-
sylation bu¡er) or the vehicle containing 10 Wg/ml Ptx for 5 min
and mixed with 1 U/ml of thrombin or 0.5 Wg/ml of SDF-1, MDC
or TARC for 10 s. Platelet aggregation was calculated by setting
platelet singlets in the vehicle or Ptx controls as 0% singlet loss, and
inhibition was derived as in Fig. 2.
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Similar to EPI, aggregation caused by SDF-1, a ligand for
CXCR4, was completely prevented by the P2Y1 antagonist
A2P5P which blocks activation of the GKq protein by ADP
[26]. Recent studies suggest that coactivation of both GKi and
GKq proteins is required for e¡ective platelet aggregation
[15,27]. Therefore, the complete inhibition of SDF-1 by
A2P5P is consistent with the inability of SDF-1 to stimulate
GKq signalling pathways. This is supported by observations in
our laboratory [11] and by Kowalska et al. [9], who reported
that SDF-1 by itself fails to mobilize calcium, which re£ects
activation of phospholipase C by GKq and GLQ proteins
[28,29].
In contrast, A2P5P only partially inhibited aggregation in-
duced by MDC and TARC, ligands for CCR4 (Fig. 3). Under
such conditions, activation of GKq by ADP was blocked, sug-
gesting that MDC and TARC by themselves can activate GKq-
dependent signalling, supported by recent evidence that MDC
induces calcium mobilization and may activate GKq [9,11].
As with EPI, early platelet aggregation stimulated by SDF-
1, MDC and TARC was resistant to the treatment with the
P2TAC antagonist AR-C69931MX (Fig. 3). Since EPI acti-
vates a GKi-coupled receptor, we hypothesized that the ‘resis-
tance’ of the chemokines to the antagonist may be because
they also stimulate GKi. The experiments using Ptx, a GKi
inhibitor, were carried out to test this hypothesis. As expected,
Ptx strongly inhibited aggregation induced by SDF-1, MDC
or TARC. This agrees with recent reported experiments show-
ing inhibition of SDF-1-induced aggregation by the toxin [10].
These results suggest that the e¡ects of the chemokines in-
volve Ptx-sensitive GKi proteins.
In conclusion, we believe that the P2Y1 ADP receptor is
particularly important for activating events leading to rapid
platelet aggregation (10 s), rather than the P2TAC receptor.
P2Y1 is also essential for the ability of the chemokines SDF-1,
MDC and TARC to initiate aggregation, which involves the
activation of Ptx-sensitive GKi proteins. However, it is impor-
tant to note that the P2TAC receptor may play a greater role
in the later sustained aggregation response as has been dem-
onstrated for ADP [18]. Our observations suggest that SDF-1
only activates GKi proteins, while MDC and TARC stimulate
not only GKi, but also GKq-dependent signalling pathways.
Further experiments will be required to understand fully the
mechanisms of platelet activation by these chemokines, in-
cluding the relative roles of K and LQ G protein subunits.
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